Menu
Recruiting NCT05379738

Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy

No phase Interventional Haematological Malignancy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 6 sessions of adapted physical activity after stem cell transplant.
Who it may be relevant to
Registry conditions: Haematological Malignancy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

APALLO : Post Allogeneic Stem Cell Transplantation Adapted Physical Activity for Patient With Hematological Malignancies

Overview

It is a study about adaptated physical activity for patients receiving a stem cell transplantation. They will benefit of 6 adaptated individuals lessons at home between 1 month and 3 months after stem cell transplantation. The study's goal is to observe if adaptated activity has an positive impact on weight loss and on life quality.

Interventions

  • Other 6 sessions of adapted physical activity after stem cell transplant
    physical assessement before and after stem cell transplant: * weight loss * brachial muscle circumference * grip strength evaluation * short physical battery test psychometric assessment before and after stem cell transplant: * quality of life questionary * physical activities questionary

Primary outcome measures

  • weight loss [Time frame: before stem cell transplantation, 1 month , 3 months, 1 year after stem cell transplantation]
  • weight loss [Time frame: before stem cell transplantation, 1 month , 3 months, 1 year after stem cell transplantation]
Secondary outcome measures (7)
  • patient's ability to attend the classes [Time frame: 3 months after stem cell transplantation]
  • body mass index [Time frame: before stem cell transplantation, 1 month , 3 months, 1 year after stem cell transplantation]
  • brachial muscle circumference [Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation]
  • grip strength evaluation [Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation]
  • short physical battery test [Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation]
  • Quality of Life Questionary C30 (QLQ-C30) [Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation]
  • in house developped physical activities questionary [Time frame: before stem cell transplantation , 1 month , 3 months, 1 year after stem cell transplantation]

Eligibility criteria

Inclusion criteria

  • Patient aged 18 or more
  • Patient with social security
  • Patient who accept the study and sign the consent form
  • Patient programmed for an allogenic stem cell transplantation

Non inclusion criteria :

  • Patients with a guardianship
  • Patients with a significant additional physic or mental disease

Exclusion criteria

  • Patients who did not receive an allogeniac stem cell transplantation
  • Patients still hospitalized between day 30 and day 100 after stem cell transplantation
  • Patients who finally refuses the study
  • Patients who develop a physical or mental incapacity to practice physical activity

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

France · 1 center
  • CHU NICE, hopital ARCHET 1, hématologie — Nice

Identifiers

NCT: NCT05379738 · 21-PP-12

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗